An observational study in Peripheral Arterial Disease, sponsored by Azienda Ospedaliera Universitaria Senese. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Azienda Ospedaliera Universitaria Senese · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Peripheral Arterial Disease with a site in Italy — 16 open to participants now, 21 under way, 2 of them phase 3. Peripheral Arterial Disease · Italy.
Among the 78 studies in Peripheral Arterial Disease with a site in Italy, this one is the 25th largest by planned enrollment of the 36 observational ones that give a count, is one of 4 that started in 2022, is one of 36 observational ones, reaches primary completion later than 0 of the 20 other live ones, and was the 60th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →16 of the 78 studies in Peripheral Arterial Disease with a site in Italy are open now. Recruiting first, the newest first:
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Sites in Italy
Ages 18+
Biotronik AG · Sites in Italy, Austria, Belgium and 5 more countries
Ages 18+
University Hospital of Ferrara · Sites in Italy
Ages 18–80
CSL Behring · Sites in Italy, United States, Argentina and 32 more countries
Ages 18+
Heart Care Foundation · Sites in Italy, Bulgaria, Denmark and 3 more countries
Ages 65+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 9 · Phase 4 8
First in 2002; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 151 across the 42 interventional studies, 204 across the 36 observational. Of the 41 that completed or were terminated, 13 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 78 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliera Universitaria Senese is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Azienda Ospedaliera Universitaria Senese has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04110327Micro Medical Solution, Inc.An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease | 2026-12-31 |
| NCT04912323R3 Vascular Inc.Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease | 2026-12-31 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
| NCT05880641EndoCore Lab s.r.l.Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 78 studies in Peripheral Arterial Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CURRENT Registry is a physician-initiated prospective, multicenter, post-market, single-arm study with a plan to include approximately 100 patients eligible to be treated with RenzanTM Peripheral Stent System.
In the last years, most of the technical evolution of materials dedicated to the treatment of femoropopliteal disease has been focused on drug-eluting technologies. However, in very complex lesions drug-coated balloons seems to be less efficient, leading to a high rate of bailout stenting with bare metal stents. Drug-eluting stents have raised expectation, providing structural scaffolding of the artery and active pharmacological treatment of the target lesion. Available evidence from the literature does not always seem to support this hypothesis.
Still, a lot of rumours have been generated on the potential local and systemic toxicity of paclitaxel.
As a consequence, in complex lesion rather than Drug Coated Balloon and Drug Eluting Stent it seems that there is need of a modern generation of nitinol stents with high Radial Resistive Force, low chronic outward forces and high fracture resistance.
The device under investigation is the Renzan™ Peripheral Stent System from Terumo MicroVention Inc. (35 Enterprise, Aliso Viejo, California 92656, USA) .
The System consists of a self-expanding nitinol stent pre-mounted on the distal portion of a rapid exchange (RX) delivery catheter. The stent is made of a nickel-titanium alloy with radiopaque markers on each end of the stent. The nitinol stent is constructed from 2 layers of tubular braided nitinol wire mesh. The outer layer consists of nitinol wire braided into a closed cell structure with flared ends. The inner layer consists of nitinol wire braided into a closed cell structure with micro sized pores. The delivery catheter has a rapid exchange port designed to allow coaxial passage of a 0.46mm (0.018") or smaller guide wire in diameter. The stent is capable of being recaptured when a minimum of 20mm of stent length remains inside the catheter.
Patients with a diagnosis of Lower Extremity Artery disease needing for endovascular treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Endovascular implantation of Renzan Stent
Endovascular treatment of LEAD patients with Renzan Stent
Primary Safety endpoint [composite]
Death + target lesion revascularization (TLR) + Major Amputation (above the ankle)
Time frame: 30 days after procedure
Primary Efficacy endpoint
Primary patency of the artery at 12 months, defined as no evidence of occlusion within the originally treated lesion based on Color Flow Doppler ultrasound in the absence of target lesion revascularization (TLR)
Time frame: 12 months
Device Success
Successful device deployment according to Instruction For Use.
Time frame: Intraoperative
Technical Success
Achievement of a final target lesion residual diameter stenosis of \<30% based on angiography.
Time frame: Intraoperative
Procedural Success
Technical and device success without procedural complication.
Time frame: Intraoperative
Any death
Cardiovascular death and non-cardiovascular death
Time frame: 1, 6, 12 24 and 36 months
Clinically-driven Target Lesion Revascularization (CD-TLR)
Any TLR associated with deterioration of patient's Rutherford category and/or increase in size of pre-existing ischemic wounds and/or occurrence of new wounds.
Time frame: 1, 6, 12 24 and 36 months
Patency of Target lesion
Defined as no evidence of restenosis or occlusion within the originally treated lesion based on a Color Flow Doppler ultrasound in the absence of target lesion revascularization (TLR). Occlusion and restenosis were defined as no color flow or an increase in peak systolic velocity ratio (PSVR) of ≥ 2.4 when compared to the proximal normal segment, respectively.
Time frame: 1, 6, 12 24 and 36 months
Limb Ischemia Improvement
Improvement in the Rutherford-Becker Clinical Improvement Scale of greater than or equal to 1. -Rutherford-Becker Classification: 0 Asymptomatic 1. Mild claudication 2. Moderate claudication 3. Severe claudication 4. Ischemic rest pain 5. Minor tissue loss 6. Major tissue loss
Time frame: 1, 6, 12 24 and 36 months
MAE (Major Adverse Event)
a composite rate of: * cardiovascular death * procedure-related arterial rupture * acute limb ischemia * stent thrombosis * clinically apparent distal embolization * target limb amputation * procedure-related bleeding event requiring transfusion
Time frame: 1, 6, 12 24 and 36 months
Index Limb Amputation
Amputation above the ankle.
Time frame: 1, 6, 12 24 and 36 months
Stent deployment performance evaluation
Operators feedback on: Pushability/Trackability, Deployment, Visibility and Precise Placement -High, Moderate and Low
Time frame: Intraoperative
Plan to share: Undecided
Started Dec 2022 (actual). Primary completion is estimated for Dec 2023, 12 months after the start.
Of 138 non-industry observational studies under Peripheral Arterial Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 12 months is below that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliera Universitaria Senese